How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-castration-resistant-prostate-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic castration-resistant prostate cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic castration-resistant prostate cancer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic castration-resistant prostate cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Zytiga	abiraterone-acetate	Johnson & Johnson	Cytochrome P450 17A1 Inhibitor	Steroid 17-alpha-hydroxylase/17,20 lyase		2011-01-01
Zytiga	Zytiga	Bukwang Pharmaceutical		Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bukwang Pharmaceutical · 1 drug in Metastatic castration-resistant prostate cancer
Johnson & Johnson · 1 drug in Metastatic castration-resistant prostate cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic castration-resistant prostate cancer:

Cite this brief

Drug Landscape (2026). Metastatic castration-resistant prostate cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-castration-resistant-prostate-cancer. Accessed 2026-06-10.

Metastatic castration-resistant prostate cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing